Niels-Erik Viby1,2, Lars Pedersen3, Thomas Kromann Lund3, Hannelouise Kissow1, Vibeke Backer3, Ebba Nexø4, Lars Thim5, Steen Seier Poulsen1. 1. Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. 2. Department of Cardiothoracic Surgery, Copenhagen University Hospital, Copenhagen, Denmark. 3. Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark. 4. Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. 5. Department of Protein Engineering, Novo Nordisk A/S, Maalov, Denmark.
Abstract
OBJECTIVE: Trefoil factor peptides (TFF) are secreted onto mucosal surfaces together with mucins and occur in high concentrations in pulmonary secretions from patients with chronic obstructive pulmonary disease (COPD). In the present study, we aimed to explore the concentrations of the peptides in serum and sputum in patients with COPD. MATERIALS AND METHODS: Thirty-five individuals were included in the study, including 11 healthy individuals, 13 indivials with asthma and 11 individuals with COPD. TFF1, TFF2 and TFF3 were measured by enzyme-linked immunosorbent assay (ELISA) in sputum induced by hypertonic saline inhalation and in serum. Total protein content in sputum was also determined. RESULTS: In the sputum samples from COPD patients, we observed an eightfold higher concentration of TFF1 and a fivefold higher concentration of TFF3 compared with controls. In the serum samples from COPD patients, we observed three-, three- and twofold higher concentrations of TFF1, TFF2 and TFF3 respectively compared with controls. CONCLUSIONS: There is increased secretion of TFF peptides in the lungs of patients with COPD, as well as significant increases in serum levels. This suggests a role for TFF peptides in the pathogenesis of pulmonary diseases with mucus hypersecretion.
OBJECTIVE: Trefoil factor peptides (TFF) are secreted onto mucosal surfaces together with mucins and occur in high concentrations in pulmonary secretions from patients with chronic obstructive pulmonary disease (COPD). In the present study, we aimed to explore the concentrations of the peptides in serum and sputum in patients with COPD. MATERIALS AND METHODS: Thirty-five individuals were included in the study, including 11 healthy individuals, 13 indivials with asthma and 11 individuals with COPD. TFF1, TFF2 and TFF3 were measured by enzyme-linked immunosorbent assay (ELISA) in sputum induced by hypertonic saline inhalation and in serum. Total protein content in sputum was also determined. RESULTS: In the sputum samples from COPDpatients, we observed an eightfold higher concentration of TFF1 and a fivefold higher concentration of TFF3 compared with controls. In the serum samples from COPDpatients, we observed three-, three- and twofold higher concentrations of TFF1, TFF2 and TFF3 respectively compared with controls. CONCLUSIONS: There is increased secretion of TFF peptides in the lungs of patients with COPD, as well as significant increases in serum levels. This suggests a role for TFF peptides in the pathogenesis of pulmonary diseases with mucus hypersecretion.
Authors: Heather L Rossi; Jorge F Ortiz-Carpena; Devon Tucker; Andrew E Vaughan; Nilam S Mangalmurti; Noam A Cohen; De'Broski R Herbert Journal: Am J Respir Cell Mol Biol Date: 2022-03 Impact factor: 6.914